Monte Rosa Therapeutics (NASDAQ:GLUE) Price Target Raised to $34.00

Monte Rosa Therapeutics (NASDAQ:GLUE) had its price objective raised by investment analysts at Guggenheim from $16.00 to $34.00 in a research note issued on Thursday,Benzinga reports. The firm presently has a “buy” rating on the stock. Guggenheim’s price objective would indicate a potential upside of 45.18% from the company’s previous close.

Other analysts also recently issued reports about the company. Zacks Research upgraded Monte Rosa Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Tuesday. Wells Fargo & Company increased their price target on Monte Rosa Therapeutics from $10.00 to $13.00 and gave the company an “equal weight” rating in a report on Friday, November 7th. Weiss Ratings restated a “sell (d)” rating on shares of Monte Rosa Therapeutics in a research note on Monday, December 29th. Cowen restated a “buy” rating on shares of Monte Rosa Therapeutics in a report on Wednesday. Finally, Wedbush reaffirmed an “outperform” rating and issued a $37.00 target price on shares of Monte Rosa Therapeutics in a research report on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Monte Rosa Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $26.80.

Monte Rosa Therapeutics Trading Up 46.3%

GLUE stock opened at $23.42 on Thursday. The company has a market cap of $1.53 billion, a price-to-earnings ratio of 73.06 and a beta of 1.60. The firm has a 50 day moving average of $15.53 and a 200-day moving average of $9.50. Monte Rosa Therapeutics has a 12-month low of $3.50 and a 12-month high of $25.15.

Monte Rosa Therapeutics (NASDAQ:GLUE) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($0.33) EPS for the quarter, beating the consensus estimate of ($0.39) by $0.06. The firm had revenue of $12.77 million for the quarter, compared to analyst estimates of $7.37 million. Monte Rosa Therapeutics had a net margin of 11.54% and a return on equity of 8.28%. Sell-side analysts forecast that Monte Rosa Therapeutics will post -1.49 earnings per share for the current fiscal year.

Institutional Trading of Monte Rosa Therapeutics

A number of institutional investors have recently made changes to their positions in GLUE. AQR Capital Management LLC increased its stake in shares of Monte Rosa Therapeutics by 459.4% during the second quarter. AQR Capital Management LLC now owns 1,283,942 shares of the company’s stock valued at $5,791,000 after acquiring an additional 1,054,406 shares during the period. Vestal Point Capital LP bought a new position in Monte Rosa Therapeutics during the 3rd quarter valued at $5,928,000. Marshall Wace LLP increased its position in shares of Monte Rosa Therapeutics by 102.4% during the 3rd quarter. Marshall Wace LLP now owns 902,834 shares of the company’s stock valued at $6,690,000 after purchasing an additional 456,754 shares during the period. Millennium Management LLC raised its stake in shares of Monte Rosa Therapeutics by 588.4% in the 3rd quarter. Millennium Management LLC now owns 444,939 shares of the company’s stock worth $3,297,000 after buying an additional 380,308 shares in the last quarter. Finally, American Century Companies Inc. lifted its holdings in shares of Monte Rosa Therapeutics by 301.4% in the second quarter. American Century Companies Inc. now owns 403,045 shares of the company’s stock valued at $1,818,000 after buying an additional 302,639 shares during the period. 79.96% of the stock is owned by institutional investors and hedge funds.

More Monte Rosa Therapeutics News

Here are the key news stories impacting Monte Rosa Therapeutics this week:

• Positive Sentiment: Interim Phase 1 data — MRT-8102 produced an 85% median reduction in high‑sensitivity CRP after 4 weeks and 94% of subjects hit CRP <2 mg/L; NEK7 degradation, IL‑1β/IL‑6 reductions and a favorable safety profile were reported. This validates the NEK7 approach and supports planned Phase 2 work, driving enthusiasm for the stock. GlobeNewswire: Interim Phase 1 Data
• Positive Sentiment: Major media and analyst reaction — Coverage from Investing.com and MSN picked up the data, and Zacks upgraded GLUE to a Strong Buy, a move that can attract momentum buyers and retail interest. Investing.com: Stock Surges After Data Zacks: Upgrade to Strong Buy
• Neutral Sentiment: Industry/analyst commentary — Seeking Alpha and QuiverQuant provide deeper reads on competitive positioning and platform validation; useful for medium-term thesis but less likely to move price alone. Seeking Alpha: Competitive MRT-8102 Results
• Negative Sentiment: Proposed $200M public offering — Monte Rosa launched an underwritten offering of common stock and pre‑funded warrants to raise $200M. This raises near‑term dilution risk and can weigh on the stock despite positive clinical news. GlobeNewswire: Proposed Public Offering
• Negative Sentiment: Interim-data and timing risk — The results are interim and the company’s planned Phase 2/expanded readouts are months away (GFORCE-1 readout H2 2026). Future trial outcomes, regulatory steps, or safety findings could reverse sentiment. GlobeNewswire: Interim Data & Forward-Looking Statements

Monte Rosa Therapeutics Company Profile

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.